The devotion, expertise, and degree of professionalism employed by the (Altasciences) team in all stages of development, and the support provided during the Clinical trial, were unprecedented.
Watch the Video
May 13, 2020
Focused on your needs, our specialists provide appropriate support for precision bioanalysis, and a full range of research services for a wide range of study types — working with you to accelerate development, meet your milestones, and ensure compliant, on-time regulatory submissions for your drug candidates.
Related Press Release
Mar 27, 2020
Altasciences has completed a Phase I study for the development of gimsilumab, a fully human monoclonal antibody that targets granulocyte-macrophage colony stimulating factor (GM-CSF), found to be up-regulated in SARS CoV-2 in patients with or at risk of developing acute respiratory distress syndrome (ARDS).
Safety assessments for both small and large molecules
Clinical pharmacology trials from first-in-human to end of Phase II
As part of our full service offering or as standalone solutions
From formulation development, phase I through commercial manufacturing, and ICH stability testing